Phaseline

Companies › Kashiv BioSciences

Kashiv BioSciences: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Other.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
KSHN001034
Selective estrogen receptor degrader (SERD); fulvestrant equivalent
ESR1Phase 1Healthy Postmenopausal Women–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06995482KSHN001034Phase 1Healthy Postmenopausal WomenOtherMay 2026

From the company's SEC filings

Complete response letters from FDA

Targets

ESR1 (1)

Companies with the same targets

Pfizer AstraZeneca Roche Eurofarma Laboratorios Eli Lilly Shanghai Best-Link Bioscience Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair Stemline Therapeutics Atossa Therapeutics GE Healthcare

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.